news
Kymab wins UK court case against Regeneron’s patent claims
The UK Supreme Court has ruled that Regeneron's patent claim regarding genetically modified mice against Kymab are invalid.
List view / Grid view
Big Pharma
Filter the results
article
Life sciences M&A activity during the global pandemic
COVID-19 has severely disrupted the lives of many people around the world. In this article, corporate partner Theo Godfrey and competition partner Russell Hoare from the life sciences team at law firm CMS Cameron McKenna Nabarro Olswang LLP consider some issues related to COVID-19 that have impacted life sciences merger…
news
GSK recalls three lots of children’s cough medicine in US
GlaxoSmithKline has voluntarily recalled two lots of Children's Robitussin® Honey Cough and Chest Congestion DM and one lot of Children's Dimetapp® Cold and Cough in the US.
article
Guide to Data Integrity
Welcome to European Pharmaceutical Review’s Guide to Data Integrity. In this edition, Charles River and Thermo Fisher Scientific showcase their unique data integrity services and discuss how they stand out from the competition.
news
Nine in 10 Americans concerned big pharma will use COVID-19 to raise drug prices
A survey of US adults has revealed that the majority are very or somewhat worried that big pharma will take advantage of the COVID-19 pandemic to increase the price of drugs.
article
An alternative to pharmaceutical pay-for-delay deals
A new paper has suggested that pay-for-delay deals could be replaced with a challenger-based system to improve access to generic drugs.
news
Gavi launches $2 billion COVID-19 vaccine funding initiative
The vaccine alliance said the Covax AMC programme is the first in a series of financing programmes to ensure low- and middle-income countries will have access to COVID-19 vaccines.
article
Why product information management is key to success in a changing pharma market
Mike Owen analyses how smart product information (PIM) management could be crucial in the future of pharma, given how large the industry continues to grow.
news
Researchers suggest system changes to limit burden of pay-for-delay deals
The changes could prevent anticompetitive practices between branded and generic pharmaceutical manufacturers, lowering drug prices for consumers.
news
Mylan partners with Gilead to manufacture remdesivir, potential COVID-19 treatment
According to a new agreement between Mylan and Gilead, the former has the rights to manufacture and distribute remdesivir in 127 countries, a drug being tested to combat COVID-19.
news
FTC accepts proposal for AbbVie to acquire Allergan for $63 billion
AbbVie and Allergan have announced the Federal Trade Commission has accepted AbbVie's pending acquisition of Allergan for $63 billion.
news
FDA approves Tabrecta for treatment of metastatic non-small cell lung cancer
The FDA has approved Tabrecta (capmatinib) for patients with metastatic non-small cell lung cancer whose tumours have a mutation that leads to MET exon 14 skipping.
article
Sterile and antiviral packaging: unlocking the potential of business continuity and resilience during COVID-19 pandemic
Amid the disruptions due to COVID-19, companies providing sterile and antiviral packaging solutions look forward to opportunities arising from the concern over viral exposure itself. Regulatory compliance will play a significant role in the rapidly shifting risk terrain.
news
Gilead files lawsuit against US federal government over alleged contract breaches
Gilead's complaint alleges five contract breaches by the US Centers for Disease Control and Prevention (CDC) and seeks a declaration of contract breach and damages.
news
Sartorius closes acquisition of selected assets of Danaher Life Sciences
Sartorius has announced the completed acquisition of some life science businesses of Danaher for a total of $825 million.